Gilead Sciences Inc
Market cap $160.5B
$129.31
GILD
$129.31
-1.18% today
Buy with €1M virtual cash · No real money
Gilead Sciences Inc (GILD) is a publicly traded company listed on the XNAS. As of July 27, 2026, Invest's signal rates GILD a Hold, with the stock up 14% over the past year. You can practice trading GILD risk-free with €1,000,000 in virtual cash.
Key stats
As of July 27, 2026
Market Cap
$160.5B
Volume
5.5M
52-wk High
$157.29
52-wk Low
$108.46
Day High
$131.65
Day Low
$129.04
P/E (TTM)
17.62
Revenue (TTM)
$29.7B
EPS (TTM)
$7.34
Performance
1M
+3.3%
6M
-1.4%
1Y
+13.9%
Invest signal · GILD
HoldAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
GILD overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev -12.2%Revenue
$7BEPS (diluted)
$1.61 per shareLatest GILD news
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?
The Motley Fool · 3d ago
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
The Motley Fool · 4d ago
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes
GlobeNewswire Inc. · Jul 17
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider
GlobeNewswire Inc. · Jul 15
Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?
The Motley Fool · Jul 12
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees
17,000
30-Day Win Rate · GILD
11 days
12 days
Last 23 sessions
How to practice trading GILD
- 1
Use the GILD buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top GILD traders on Invest
Full leaderboardFrequently asked questions
Is GILD a good stock to buy right now?
As of July 27, 2026, Invest's signal rates GILD a Hold, based on its price trend, valuation, and fundamentals (P/E around 17.6), with the stock up 14% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading GILD risk-free first.
What is Gilead Sciences Inc's (GILD) market cap?
Gilead Sciences Inc has a market capitalization of approximately $160.5B, on trailing-twelve-month revenue of about $29.7B.
How has GILD stock performed?
GILD is up 14% over the past year and down 1% over six months. Its 52-week range runs roughly from $108.46 to $157.29. Past performance doesn't predict future results.
How can I practice trading GILD for free?
On Invest you get €1,000,000 in virtual cash and can buy GILD at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.
Compare GILD with peers